Collaborative Medicinal Development LLC wins AU$1 million gran... - 18 April 2019 03:58

MILL VALLEY, California and MELBOURNE, Australia, April 18, 2019 /PRNewswire-AsiaNet/ -- --Collaborative Medicinal Development LLC (CMD), announces that it was awarded a AU$1 million grant from FightMND to support a Phase 2 study of CuATSM for treatment ALS (amyotrophic lateral sclerosis), also known as Lou Gehrig's disease, or Motor ...

  Financial year 2018: Boehringer Ingelheim grows and invests - 17 April 2019 18:30

INGELHEIM, Germany, April 17, 2019 /PRNewswire-AsiaNet/ -- -- Well-filled research pipeline in oncology, fibrotic diseases, immunology and metabolic diseases -- Operating growth outpaces the market in all businesses -- Technical integration of the animal health business acquired ...

  MedShift Announces Expansion to Australia and New Zealand - 17 April 2019 09:00

CHARLOTTE, N.C., April 17, 2019 /PRNewswire-AsiaNet/ -- MedShift ( https://c212.net/c/link/?t=0&l=en&o=2436130-1&h=222409809&u=https%3A%2F%2Fmedshift.com%2F&a=MedShift ), the premier innovator in medical aesthetic technology, announced today that it will bring its product and service offerings to Austr...

  NOVASEP and THERAVECTYS Enter Into a New License Agreement on ... - 16 April 2019 18:00

PARIS and LYON, France, April 16, 2019 /PRNewswire-AsiaNet/ -- This agreement supports the growing demand for lentivector-based gene therapies, immunotherapies and vaccines Novasep, a leading supplier of services and technologies for the life sciences industry, and Theravectys, a discovery & clinical devel...

  Ortho's VITROS(R) High Sensitivity Troponin I Assay for the Di... - 16 April 2019 15:55

RARITAN, New Jersey, Apr. 16, 2019 /PRNewswire-AsiaNet/-- -- Next-generation assay aids in diagnosing heart attacks faster and more accurately, and is enabled on the company's newest analyzer, the VITROS(R) XT 7600 Integrated System Ortho Clinical Diagnostics, a global leader of in vitro diagnostics...

  Tessa Therapeutics Announces Collaboration with MSD Investigat... - 16 April 2019 09:15

SINGAPORE, April 16, 2019 /PRNewswire-AsiaNet/ -- The collaboration will evaluate the safety and efficacy of Tessa's armored human papillomavirus-specific T cell (HPVST) therapy combined with MSD's KEYTRUDA (R) (pembrolizumab) to address the limited number of effective treatment options for metas...

  #RosaceaNoFilter: Online Influencers Take the Lead in Raising ... - 15 April 2019 18:40

LAUSANNE, Switzerland, April 15, 2019 /PRNewswire-AsiaNet / -- As part of its ongoing commitment to raising awareness of rosacea and the hidden burden of the disease, Galderma is collaborating with top social media influencers this Rosacea Awareness Month, to encourage people with rosacea to speak up and shar...

  Stryker Launches Next Generation Flow Diverter for Treatment o... - 15 April 2019 06:00

KALAMAZOO, Michigan, USA, Apr. 15, 2019 /PRNewswire-AsiaNet/-- Stryker announces the availability of the Surpass Evolve Flow Diverter following CE mark approval in March. Surpass Evolve is Stryker's latest entrant into the flow diversion space for the treatment of brain aneurysms. Photo - https://mma.prne...

  World First Development of an Arsenic-Peptide to Target Cancer - 12 April 2019 16:00

WOLLONGONG, NSW, Australia, Apr. 12, 2019/Medianet-International-AsiaNet/-- Australian pharmaceutical firm, Phebra, has announced a collaboration and licensing agreement with the University of Wollongong (UOW) to continue development of newly patented arsenic compounds that potentially treat haematologic malignancies an...

  Anpac Bio CDA Liquid Biopsy Technology Selected by FAST COMPAN... - 11 April 2019 23:45

SACRAMENTO, California, April 11, 2019 /PRNewswire-AsiaNet/ -- The editors and judges of Fast Company Magazine selected Anpac Bio-Medical Science Company's ( https://c212.net/c/link/?t=0&l=en&o=2433269-1&h=587923662&u=http%3A%2F%2Fwww.anpacbio.com%2F&a=Anpac+Bio-Medical+Science+Company ), "Cancer Differentiat...